EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A randomized treatment trial of intravenous pamidronate and oral alendronate in Pagets disease Early results



A randomized treatment trial of intravenous pamidronate and oral alendronate in Pagets disease Early results



Bone (New York) 24(5 SUPPL ): 67S-68S




(PDF emailed within 0-6 h: $19.90)

Accession: 034319299

Download citation: RISBibTeXText

DOI: 10.1016/s8756-3282(99)00064-2



Related references

A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone 34(4): 747-754, 2004

Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research 21(1): 132-140, 2005

Treatment of pagets disease of bone with intravenous pamidronate. British Journal of Rheumatology 29(ABSTR SUPPL 2): 138, 1990

Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. Netherlands Journal of Medicine 60(8): 315-319, 2002

Treatment of Pagets disease with oral alendronate. Calcified Tissue International 56(5): 505, 1995

Treatment of Pagets disease of bone with intravenous pamidronate A comparison of two different modes of treatment. Bone (New York) 20(4 SUPPL ): 56S, 1997

Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial. Oncotargets and Therapy 9(): 4173-4180, 2016

A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Alimentary Pharmacology and Therapeutics 18(11/12): 1121-1127, 2003

Heterogeneity of responses to intravenous pamidronate in patients with Pagets disease of bone. Journal of Bone & Mineral Research 15(Suppl 1): S443, September, 2000

Clinical value of osteocalcin in Pagets disease treated with intravenous pamidronate disodium. Bone (New York) 20(4 SUPPL ): 55S, 1997

Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. Journal of Clinical Endocrinology and Metabolism 83(7): 2324-2330, 1998

Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral)+metronidazole (intravenous/oral) with ceftriaxone (intravenous)+metronidazole (intravenous/oral) for the treatment of intra-abdominal infections. International Journal of Antimicrobial Agents 21(1): 49-57, 2003

The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis. Osteoporosis International 16(11): 1432-1435, 2005

Experience of treating 218 patients with pagets disease of bone using intravenous 3 aminohydroxypropylidene 1 1 bisphosphonate pamidronate apd. Cohn, D V , F H Glorieux And T J Martin International Congress Series, 886 Calcium Regulation And Bone Metabolism: Basic And Clinical Aspects; Proceedings Of The 10th International Conference on Calcium Regulating Hormones And Bone Metabolism, Montreal, Quebec, Canada, September 9-14, 1989 Xxi+533p Elsevier Science Publishers B V : Amsterdam, Netherlands; (Dist in The Usa And Canada By Elsevier Science Publishing Co , Inc : New York, New York) Illus 509-514, 1990